Cell Biochemistry and Biophysics

, Volume 71, Issue 2, pp 777–784 | Cite as

Effectiveness of Combined 131I-chTNT and Radiofrequency Ablation Therapy in Treating Advanced Hepatocellular Carcinoma

  • Jianfei Tu
  • Jiansong Ji
  • Fazong Wu
  • Yonghui Wang
  • Dengke Zhang
  • Zhongwei Zhao
  • Xihui Ying
Original Paper
First Online:

Abstract

To investigate the effectiveness of monoclonal antibody (131I-chTNT) and radiofrequency ablation (RFA) combination therapy in treating middle-advanced stage hepatocellular carcinoma (HCC). Thirty-four patients diagnosed with HCC patients, divided into two groups comprised of 22 and 12 cases were included in this retrospective study. The two groups received RFA with or without (131I-chTNT) therapy, respectively. The patients in these groups were followed up for a median of 31 and 35 months, respectively. Patient survival was evaluated using Kaplan–Meier method and safety profiles were determined by analyzing liver, thyroid, and bone marrow toxicities. This retrospective study showed that survival time of the patients who received combination therapy was significantly longer than that of the RFA group (P = 0.052). The median progress-free survival of patients in the two groups was 23 and 7 months, respectively, and the difference was significant (P = 0.04). Tumor recurred in 3.5–8.7 months in four of the combination group patients, among which three had newly developed lesions. The red blood cells and platelets counts were not altered on day 7 and 1 month of the treatment, however, number of white blood cells was significantly increased on day 7 which was reversed back to the normal range in 2 weeks. The ALT and AST were also not significantly altered on day 7 and 1 month of therapy. In middle-advanced stage HCC patients, the combination of 131I-chTNT and RFA therapy was found to be significantly more effective than the RFA treatment alone as assessed in short-term follow-up. However, the dose we used was insufficient to completely block the local recurrence of the lesions with a diameter of 5 cm or larger.

Keywords

Liver neoplasm Radiofrequency ablation Effectiveness Radioimmunotherapy 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This work was supported by Program for Science and Technology Department of Zhejiang Province (2010C33113).

Conflict of interest

The authors have no disclosures to make.

References

  1. 1.
    Lewandowski, R. J., Mulcahy, M. F., Kulik, L. M., et al. (2010). Chemoembolization for hepatocellular carcinoma comprehensive imaging and survival analysis in a 172-patient cohort. Radiology, 255, 955–965.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Ye, S. L., Takayama, T., Geschwind, J., et al. (2010). Current approaches to the treatment of early hepatocellular carcinoma. Oncologist, 15, 34–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Yin, J. H., Li, N., Han, Y. F., et al. (2013). Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study. Journal of Clinical Oncology, 31, 3647–3655.PubMedCrossRefGoogle Scholar
  4. 4.
    Feng, K., Yan, J., Li, X. W., et al. (2012). A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. Journal of Hepatology, 57, 794–802.PubMedCrossRefGoogle Scholar
  5. 5.
    Lencioni, R., & Crocetti, L. (2012). Local-regional treatment of hepatocellular carcinoma. Radiology, 262, 43–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Livraghi, T., Meloni, F., Morabito, A., & Vettori, C. (2004). Multimodal image-guided tailored therapy of early and intermediate hepatocellular carcinoma: Long-term survival in the experience of a single radiologic referral center. Liver Transplantation, 10(2 suppl 1), S98–S106.PubMedCrossRefGoogle Scholar
  7. 7.
    Shiina, S., Teratani, T., Obi, S., et al. (2005). A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology, 129(1), 122–130.PubMedCrossRefGoogle Scholar
  8. 8.
    Kong, W.-T., Zhang, W.-W., Qiu, Y.-D., et al. (2009). Major complications after radiofrequency ablation for liver tumors: Analysis of 255 patients. World Journal of Gastroenterology, 15(21), 2651–2656.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Seror, O. N., Kontchou, G., Ibraheem, M., et al. (2008). Large (≥5.0 cm) HCCs: Multipolar RF ablation with three internally cooled bipolar electrodes—initial experience in 26 patients. Radiology, 248, 288–296.PubMedCrossRefGoogle Scholar
  10. 10.
    Vincenzo, A., Stefano, P., Claudio, M. P., et al. (2008). Complications of laser ablation for hepatocellular carcinoma: A multicenter study. Radiology, 246, 944–955.Google Scholar
  11. 11.
    Lau, W., & Lai, C. H. (2008). Hepatocellular carcinoma current management and recent advances. Hepatobiliary Pancreatic Diseases International, l7, 237–257.Google Scholar
  12. 12.
    Boerman, O. C., Koppe, M. J., Postema, E. J., et al. (2007). Radionuclide therapy of cancer with radiolabeled antibodies. Anticancer Agents in Medicinal Chemistry, 7, 335–343.CrossRefGoogle Scholar
  13. 13.
    Guglielmi, A., Ruzzenente, A., Valdegamberi, A., et al. (2008). Radiofrequency ablation versus resection for the treatment of hepatocellular carcinoma in cirrhosis. Journal of Gastrointestinal Surgery, 12, 192–198.PubMedCrossRefGoogle Scholar
  14. 14.
    Goldberg, S. N., Girnan, G. D., Lukyanov, A. N., et al. (2002). Percutaneous tumor ablation: Increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology, 222(3), 797–804.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamakado, K., Nakatsuka, A., Takaki, H., et al. (2008). Early-stage hepatocellular carcinoma: Radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology, 247, 260–266.PubMedCrossRefGoogle Scholar
  16. 16.
    Harris, D. A., Pellikka, R., Gasser, O., et al. (2009). In-line radiolabeling: A novel continuous-flow system for commercial-scale protein labeling. Journal of Nuclear Medicine, 50, 1178–1186.PubMedCrossRefGoogle Scholar
  17. 17.
    Jong, G. M., Boerman, O. C., Heskamp, S., et al. (2009). Radioimmunotherapy prevents local recurrence of colonic cancer in an experimental model. British Journal of Surgery, 96, 314–321.PubMedCrossRefGoogle Scholar
  18. 18.
    Chen, S. L., Like, Yu., Jiang, C. Y., et al. (2005). Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer. Journal of Clinical Oncology, 23, 1538–1547.PubMedCrossRefGoogle Scholar
  19. 19.
    Wilder, R., DeNardo, G., & DeNardo, S. (1996). Radioimmunotherapy: Recent results and future directions. Journal of Clinical Oncology, 14, 1383–1400.PubMedGoogle Scholar
  20. 20.
    Meredith, R., LoBuglio, A., & Spencer, E. (1997). Recent Progress in Radioimmunotherapy for Cancer. Oncology, 11, 979–984.PubMedGoogle Scholar
  21. 21.
    Knox, S., & Meredith, R. (2000). Clinical Radioimmunotherapy. Seminars in Radiation Oncology, 10, 73–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Zheng, S.-G., Xu, H.-X., Guo, L.-H., Liu, L.-N., & Lu, F. (2014). The safety and treatment response of combination therapy of radioimmunotherapy and radiofrequency ablation for solid tumor: A study in vivo. PLoS One, 9(5), e96539.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Yu, L., Ju, D. W., Chen, W., et al. (2006). 131I-chTNT Radioimmunotherapy of 43 Patients with Advanced Lung Cancer. Cancer Biotherapy Radiopharmaceuticals, 21(1), 5–14.PubMedCrossRefGoogle Scholar
  24. 24.
    Gao, J., & Zhu, J. Y. (2012 [2011 edition]). Read of the primary liver cancer diagnosis and treatment norms by The Ministry of Health. Chinese Journal of General Surgery, 27(8), 693–699.Google Scholar
  25. 25.
    Llovet, J. M., Di Bisceglie, A. M., Bruix, J., et al. (2008). Design and endpoints of clinical trials in hepatocellular carcinoma. Journal of the National Cancer Institute, 100, 698–711.PubMedCrossRefGoogle Scholar
  26. 26.
    Li, Bl., Chen, S. L., & Xu, Z. Q. (2009). Biodistribution of iodine-131-labeled chimeric monoclonal antibody in patients following intratumoral administration in advanced lung carcinoma. Fudan University Journal of Medical Sciences, 36, 475–478.Google Scholar
  27. 27.
    Shibata, T., Isoda, H., Hirokawa, Y., et al. (2009). Small hepatocellular carcinoma: Is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology, 252, 905–913.PubMedCrossRefGoogle Scholar
  28. 28.
    Peng, Z. W., Zhang, Y. J., Chen, M. S., et al. (2013). Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: A prospective randomized trial. Journal of Clinical Oncology, 31, 426–432.PubMedCrossRefGoogle Scholar
  29. 29.
    Zhu, A. X., & Salem, R. (2013). Combining transarterial chemoembolization with radiofrequency ablation for hepatocellular carcinoma: One step forward? Journal of Clinical Oncology, 31, 406–408.PubMedCrossRefGoogle Scholar
  30. 30.
    Zhang, Y.-J., Liang, H.-H., Chen, M.-S., et al. (2007). Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: A prospective randomized trial. Radiology, 244, 599–607.PubMedCrossRefGoogle Scholar
  31. 31.
    Takaki, H., Yamakado, K., Nakatsuka, A., et al. (2007). Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinoma 5 cm or smaller: Risk factors for local tumor progression. Journal of Vascular and Interventional Radiology, 18(7), 856–861.PubMedCrossRefGoogle Scholar
  32. 32.
    Kuang, M., Lu, M.-D., Xie, X.-Y., et al. (2009). Ethanol ablation of hepatocellular carcinoma up to 5.0 cm by using a multipronged injection needle with high-dose strategy. Radiology, 253, 552–561.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jianfei Tu
    • 1
  • Jiansong Ji
    • 1
  • Fazong Wu
    • 1
  • Yonghui Wang
    • 2
  • Dengke Zhang
    • 1
  • Zhongwei Zhao
    • 1
  • Xihui Ying
    • 1
  1. 1.Department of Radiology and Interventional RadiologyLishui Central HospitalLishuiChina
  2. 2.Department of OncologyLishui Central HospitalLishuiChina

Personalised recommendations